The efficacy of anti-PD-1 treatment was improved by genetic deficiency or inhibition of CXCR1/2 in murine models of oral and lung carcinomas, rhabdomyosarcomas [136], pancreatic adenocarcinoma [147], and prostate cancer [155]. The gene discussed is CXCR1; the disease is rhabdomyosarcoma.